Loading…
Based on limited metadata, Valentus, Inc. received an FDA Warning Letter on November 30, 2020, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the complete regulatory concerns and required corrective actions, the full Warning Letter text would need to be reviewed.